Abeona Therapeutics Inc. (NASDAQ:ABEO)
Industry: Biotechnology

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, engineered cell therapy that is in a Phase 1/2a clinical trialfor recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.

Current Quote*
Last: $6.235
Change: 0.000
Book: $2.924
Volume: 645,601

As Of: 05/30 16:07 ET
*Quotes delayed by 20min.

BuyIns.Net Alerts for Symbol ABEO

Graphs for ABEO


3 Month Graph


6 Month Graph


1 Year Graph